Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Featured Story

Gilead won a valuable FDA voucher with its Veklury approval, but patient advocates are urging the company to give it up: report

By Eric Sagonowsky

Gilead Sciences has the most successful COVID-19 drug so far in Veklury, an antiviral also known as remdesivir that was originally developed as part of research programs into hepatitis C and respiratory syncytial virus. While there’s an ongoing debate about the med’s efficacy against the novel coronavirus, the drugmaker is already reeling in big sales in the indication—and has also gained an added benefit it doesn't deserve, a patient advocacy group argues.

Clover Biopharma nabs $250M+ for COVID-19 vaccine in expanded CEPI deal

By Amirah Al Idrus

China’s Clover Biopharma is getting another boost as it gears up for a global, pivotal trial of its COVID-19 vaccine. CEPI is adding $258.5 million to a deal the partners initially struck in April this year, which will see the candidate through a phase 2/3 study and licensure in China and other countries.

Humana posted major profit in Q3. But the good times are expected to end in Q4, they said

By Paige Minemyer

Humana brought in $1.3 billion in profit for the third quarter, the insurer reported Tuesday morning. That represents a 94.5% climb from net income in the third quarter of 2019, which was $689 million.

The best COVID warning system? Poop and pooled spit, says one Colorado school

By Rae Ellen Bichell, Kaiser Health News

In normal times, these researchers study stem cells and muscular dystrophy. Now, they are on the front lines against potential COVID-19 outbreaks on a campus with more than 23,000 undergraduates.

CMS expanding payments for new home dialysis equipment

By Tina Reed

The Trump administration finalized another rule aimed at boosting end-stage renal disease patients' access to home dialysis by allowing certain new equipment and supplies to qualify for an additional Medicare payment.

Biopharma roundup: Pfizer to bypass McKesson for U.S. shot rollout

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

Pfizer will handle shot distribution itself, instead of going through the CDC's central distributor, McKesson. T-cell immunity to the virus seems to endure, a new study found. Plus, more children are contracting COVID-19, the American Academy of Pediatrics said.

Healthcare roundup: CDC warns of COVID risks for pregnant women

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 Tracker